Gastric Cancer Reagents

Home > Featured Products > Oncology Research > Gastric Cancer

Gastric and gastroesophageal junction (GEJ) cancers are classified by molecular subtypes — MSI-H, EBV-positive, CIN (HER2-amplified), and GS (CDH1-mutant). Claudin 18.2, FGFR2b, and immune checkpoints are reshaping targeted therapy. abinScience provides reagents for HER2, Claudin 18.2, PD-L1, FGFR, MET, and E-cadherin/CDH1. RUO

Key Biomarkers & Targets

HER2 / ErbB2

Trastuzumab Target

Amplified in ~15–20% of gastric/GEJ cancers. Trastuzumab backbone of first-line therapy. 110+ antibodies and biosimilar proteins.

Antibodies • Proteins • Biosimilars

Claudin 18.2

CLDN18.2

Tight junction protein expressed in ~60% of gastric cancers. Zolbetuximab target — first CLDN18.2 therapy approved. 51+ products.

Antibodies • Biosimilars

PD-1 / PD-L1

CD279 / CD274

Nivolumab and pembrolizumab approved for advanced gastric cancer. 260+ checkpoint antibodies, proteins, and biosimilars.

Antibodies • Proteins • Biosimilars

FGFR2b

Fibroblast Growth Factor Receptor

FGFR2b overexpression guides bemarituzumab eligibility. 76 FGFR antibodies and recombinant proteins.

Antibodies • Proteins

E-cadherin / CDH1

Cell Adhesion / Diffuse Gastric

CDH1 loss defines diffuse-type and hereditary gastric cancer (HDGC). 70 antibodies and recombinant proteins.

Antibodies • Proteins

MET / CEA / MUC1

Amplification & Serum Markers

MET amplification in ~5% of gastric cancer. CEA and MUC1 for serum monitoring and ADC targets.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for Gastric Cancer

Claudin 18.2 & HER2 Dual CoverageThe two key targetable biomarkers in gastric cancer, with research-grade biosimilar proteins (ELISA/FACS validated) for drug comparability studies.

Molecular Subtype ProfilingMSI/MMR panel, E-cadherin/CDH1 (diffuse type), FGFR2b, and HER2 reagents for classifying gastric cancer into actionable molecular subtypes.

Checkpoint & Anti-Angiogenic PanelPD-1, PD-L1, CTLA-4, VEGF/VEGFR reagents supporting combination immunotherapy and ramucirumab-related research.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

CLDN18.2 patient stratification: Use anti-Claudin 18.2 antibodies (IHC) to score CLDN18.2 expression intensity and percentage in gastric cancer FFPE tissue for zolbetuximab eligibility research.
HER2 + PD-L1 dual assessment: Combine anti-HER2 (IHC) and anti-PD-L1 (IHC) antibodies for simultaneous targetable biomarker profiling in gastric/GEJ cancer specimens.
FGFR2b-targeted therapy development: Quantify FGFR2b expression with our antibodies and recombinant FGFR2b proteins for bemarituzumab-class biosimilar binding and potency assays.
Hereditary diffuse gastric cancer (HDGC): Profile E-cadherin/CDH1 expression loss by IHC and WB in CDH1 germline mutation carriers and sporadic diffuse gastric cancer samples.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you offer Claudin 18.2 antibodies for IHC?

Research-grade CLDN18.2 biosimilar proteins (zolbetuximab, osemitamab, gresonitamab) with ELISA and FACS validation. Detection-grade IHC antibodies not yet in catalog.

Which HER2 antibodies are recommended for gastric cancer IHC?

Anti-HER2/ErbB2 clone 1A064 with ELISA, IHC, and WB validation. Research-grade HER2 biosimilar proteins (disitamab, trastuzumab, pertuzumab) also available. Research use only.

Do you carry E-cadherin antibodies for diffuse-type gastric cancer?

Yes. Anti-E-cadherin/CDH1 antibodies and recombinant CDH1 proteins available. See product pages for validated applications.

What MSI/MMR reagents are available for gastric cancer?

Antibodies for MLH1, MSH2, MSH6, and PMS2 available. See product pages for validated applications and species.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.